This finding was consistent with previous data and suggests that the vascular effects of PACAP are mediated by the VPAC receptors rather than the PAC1 receptor,95 making targeting PAC1 an exciting strategy for migraine potentially without substantial vascular effects, akin to specific targeting of the 5HT1F receptor in the serotoninergic system. Here, ADCYAP1 is linked to migraine disorder.